Exploration and exploitation in innovation systems: The case of pharmaceutical biotechnology

Research Policy

Volumn 35, Issue 1, 2006, Pages 1-23

  Gilsing, Victor ^a   Nooteboom, Bart ^b  

^a EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^b TILBURG UNIVERSITY   (Netherlands)

Author keywords

Exploitation; Exploration; Pharmaceutical biotechnology; Sectoral systems

Indexed keywords

DRUG PRODUCTS; INDUSTRIAL RESEARCH;

EXPLOITATION; EXPLORATION; PHARAMCEUTICAL BIOTCHNOLOGY; SECTORAL SYSTEMS;

BIOTECHNOLOGY;

EID: 31844436633     PISSN: 00487333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.respol.2005.06.007     Document Type: Article

References (74)

1. W.J. Abernathy, and J.M. Utterback Patterns of industrial innovation Technology Review 81 June/July 1978 41 47
2. Aharonson, B.S., Baum, J.A.C., Feldman, M.P., 2004. Industrial clustering and the returns to inventive activity: Canadian biotechnology firms, 1991-2000, no. 04-03. DRUID Working Paper (www.druid.dk/wp/wp.html ).
3. A. Allansdottir, A. Bonnaccorsi, A. Gambardella, M. Mariani, F. Pammolli, and M. Riccaboni Innovation and Competitiveness in Biotechnology: A European Perspective, Background Report 2001 DG-Enterprise EU, Brussels
4. Allansdottir, A., Bonnaccorsi, A., Gambardella, A., Mariani, M., Pammolli,F., Riccaboni, M., 2002. Innovation and competitiveness in biotechnology, Enterprise papers, 7-2002. DG-Enterprise, EU, Brussels.
5. Argyris, C., Schön, D., 1978. Organizational Learning. Addison-Wesley, Reading (Ma).
6. A. Arora, and A. Gambardella The changing technology of technological change: general and abstract knowledge and the division of innovative labour Research Policy 23 1994 523 532
7. R.A. Bettis, and C.K. Prahalad The dominant logic: retrospective and extension Strategic Management Journal 16 1995 5 14
8. Biopartner, 2000. The Netherlands Life Sciences Report 2000. Biopartner, Leiden.
9. Biopartner, 2001. The Netherlands Life Sciences Report 2001. Biopartner, Leiden.
10. Biopartner, 2002. The Netherlands Life Sciences Report 2001. Biopartner, Leiden.
11. S. Brusoni, and A. Geuna An international comparison of sectoral knowledge bases: persistence and integration in the pharmaceutical industry Research Policy 32 2003 1897 1912
12. M. Callon From science as an economic activity to socioeconomics of scientific research, the dynamics of emergent and consolidated techno-economic networks P.P. Mirowski EM. Sent Science Bought and Sold: Essays in the Economics of Science 2002 University of Chicago Chicago 277 317
13. S. Casper, and H. Kettler National institutional frameworks and the hybridization of entrepreneurial business models: the German and UK biotechnology sectors Industry and Innovation 8 2001 5 30
14. G.H. Degenaar, and F.H.A. Janszen Biotechnologie op weg naar het jaar 2000, Een toekomstperspectief voor de Nederlandse industrie 1996 Erasmus Universiteit Rotterdam
15. P.J. DiMaggio, and W.W. Powell The iron cage revisited: institutional isomorphism and collective rationality in organizational fields American Sociological Review 48 1983 147 160
16. G. Dosi, and L. Marengo On the tangled intercourses between transaction cost economics and competence-based views of the firm: a comment N. Foss V. Mahnke Competence, Governance and Entrepreneurship 2000 Oxford University Press Oxford 80 92
17. C. Edquist Systems of Innovation, Technologies, Institutions and Organizations 1997 Pinter London
18. Ernst, Young, 1999. European Life Sciences 1999. Sixth Annual Report. Ernst and Young Ltd., London.
19. Ernst, and Young Focus on Fundamentals, the Biotechnology Report 2001 Ernst and Young Ltd. London
20. Ernst, and Young Integration, European Life Sciences Report 2001 Ernst and Young Ltd. London
21. Ernst, and Young What's in a Name: Leveraging a Quality Brand in the Health Sciences Marketplace 2001 Ernst and Young Ltd. London
22. Ernst, and Young Beyond Borders, the Global Biotechnology Report 2002 Ernst and Young Ltd. London
23. C.M. Enzing Bijlage bij de integrale nota biotechnologie 2000 Ministerie van Economische Zaken Den Haag
24. Enzing, C.M., Kern, S., 2002. The Dutch Biotechnology Innovation System: An Inventory and Assessment of the Major Developments Since 1994. TNO-STB Report 02-04, TNO-STB, Delft.
25. Enzing, C.M., Kern, S., Giessen, A. v.d., 2003. R&D samenwerking door de Nederlandse biotechnologie industrie: uitkomsten van een survey. TNO-STB rapport 03-22, TNO-STB, Delft.
26. C. Enzing Dutch cluster policy and the character of regional concentration of biotech firms G. Fuchs Biotechnology in Comparative Perspective 2003 Routledge London 169 191
27. Enzing, C., Kern, S., van de Giessen, A., 2005. The Dutch biopharmaceutical and food biotechnology innovation system. OECD Proceedings, The Biopharmaceutical Innovation System in Eight OECD Countries, Case Studies on Structure, Performance, Innovation Barriers and Drivers. OECD, Paris.
28. EZ, 1998. Pharmaceuticals, Technologie-radar, Ministerie van Economische Zaken. Den Haag, pp. 65-67.
29. EZ, 2000. Integrale nota biotechnologie, Ministerie van Economische Zaken. Den Haag.
30. A. Gambardella Competitive advantage from in-house scientific research: the US pharmaceutical industry in the 1980s Research Policy 21 1992 391 407
31. A. Gambardella Science and Innovation in the US Pharmaceutical Industry 1995 Cambridge University Press Cambridge
32. A. Gambardella, L. Orsenigo, and F. Pammolli Global Competitiveness in Pharmaceuticals: A European Perspective 2000 DG-Enterprise EU, Brussels
33. O. Gassman, G. Reepmeyer, and M. von Zedtwitz Leading Pharmaceutical Innovation 2004 Springer Berlin
34. M. van Geenhuizen, and B. van der Knaap R&D and regional networks dynamics in Dutch pharmaceutical industry Journal of Economic and Social Geography 88 1997 307 320
35. M. van Geenhuizen How small biotechnology firms survive in the Dutch pharmaceutical industry: an exploratory analysis R.P. Oakey New Technology-Based in the 1990's 1999 Paul Chapman London 200 212
36. Gilsing, V.A., 2005. The dynamics of innovation and interfirm networks, exploration, exploitation and co-evolution. Edward Elgar, Cheltenham.
37. E.M. Gordon, R.W. Barrett, W.J. Dower, S.P.A. Fodor, and M. Gallop Applications of combinatorial technologies to drug discovery, combinatorial organic synthesis library screening stategies and future directions Journal of Medicinal Chemistry 37 1994 1385 1401
38. R. Henderson The evolution of integrative competence, innovation in cardiovascular drug discovery Industrial and Corporate Change 3 1994 607 630
39. Henderson, R., Orsenigo, L., Pisano, G., 1999. The pharmaceutical industry and the revolution in molecular biology: interactions among scientific, institutional and organizational change. In: Mowery, D.C., Nelsoni, R.R. (Eds.), Sources of Industrial Leadership. Cambridge University Press, New York, pp. 267-311.
40. Knoke, D., Kuklinski, J.H., 1982. Network analysis. Sage Publications, Beverly Hills.
41. A. Jungmittag G. Reger Th. Reiss Changing Innovation in the Pharmaceutical Industry, Globalisation and New Ways of Drug Development 2000 Springer Berlin
42. B.-A. Lundvall National Systems of Innovation 1992 Pinter London
43. F. Malerba Sectoral systems of innovation and production Research Policy 31 2002 247 264
44. F. Malerba Sectoral Systems of Innovation 2004 Cambridge University Press Cambridge
45. F. Malerba, and S. Breschi Sectoral innovation systems: technological regimes, Schumpetarian dynamics and spatial boundaries C. Edquist Systems of Innovation, Technologies, Institutions and Organizations 1997 Pinter London
46. J. March Exploration and exploitation in organizational learning Organization Science 2 1991 71 87
47. O. Marsili The anatomy and Evolution of Industries, Technological Change and Industrial Dynamics 2001 Edward Elgar Cheltenham
48. M. McKelvey Co-evolution in commercial genetic engineering Industrial and Corporate Change 6 1997 503 532
49. M. McKelvey, and L. Orsenigo Pharmaceuticals as a sectoral innovation system F. Malerba Sectoral Systems of Innovation 2004 Cambridge University Press Cambridge
50. D.C. Mowery R.R. Nelson Sources of Industrial Leadership, Studies of Seven Industries 1999 Cambridge University Press New York
51. R.R. Nelson National Innovation Systems: A Comparative Analysis 1993 Oxford University Press New York
52. R.R. Nelson The co-evolution of technology, industrial structure and supporting institutions Industrial and Corporate Change 1 1994 47 63
53. P. Nightingale Economies of scale in experimentation: knowledge and technology in pharmaceutical R&D Industrial and Corporate Change 9 2000 315 359
54. B. Nooteboom Learning and Innovation in Organizations and Economies 2000 Oxford University Press Oxford (Paperback edition published in 2001)
55. B. Nooteboom Trust: Forms, Foundations, Functions, Failures and Figures 2002 Edward Elgar Cheltenham
56. B. Nooteboom Interfirm Collaboration, Learning and Networks, an Integrated Approach 2004 Routledge London
57. OECD Proceedings, 2005. The Biopharmaceutical Innovation System in Eight OECD Countries, Case Studies on Structure, Performance, Innovation Barriers and Drivers. OECD, Paris.
58. L. Orsenigo, F. Pammolli, M. Riccaboni, A. Bonaccorsi, and G. Turchetti The evolution of knowledge and the dynamics of an industry network Journal of Management and Governance 1 1998 147 175
59. L. Orsenigo, F. Pammolli, and M. Riccaboni Technological change and network dynamics, lessons from the pharmaceutical industry Research Policy 30 2001 485 508
60. J. Owen-Smith, and W.W. Powell Knowledge networks as channels and conduits: The effects of spillovers in the Boston biotechnology community Organization Science 15 1 2004 5 21
61. G. Pisano Pharmaceutical biotechnology R.R. Nelson D.G. Victor B. Steil Technological Innovation and Economic Performance 2002 Princeton University Press Princeton 346 366
62. W.W. Powell, K.W. Koput, and L. Smith-Doerr Inter-organizational collaboration and the locus of innovation: networks of learning in biotechnology Administrative Science Quarterly 41 1996 116 145
63. Reiss, Th., Reger, G., Jungmittag A. (Eds.), 2000. Changing Innovation in the Pharmaceutical Industry, Globalisation and New Ways of Drug Development. Springer, Berlin.
64. Roijakkers, A.H.W.M, 2003. Interfirm cooperation in high-tech industries, a study of R&D-partnerships in pharmaceutical biotechnology, Ph.D. thesis. MERIT, Universitaire Pers Maastricht, Maastricht.
65. N. Roijakkers, J. Hagedoorn, and M. van Kranenburg Dual market structures and the likelihood of repeated ties, evidence from pharmaceutical biotechnology Research Policy 34 2005 235 245
66. F.M. Santos The co-evolution of firms and their knowledge environment: insights from the pharmaceutical industry Technological Forecasting and Social Change 70 2003 687 715
67. J. Senker Biotechnology and Competitive Advantage, Europe's Firms and the US Challenge 1998 Edward Elgar Cheltenham
68. Senker, J., van Zwanenberg, P., 2001. European Biotechnology Innovation Systems, Final Report, TSER-project no. SOE1-CT98-1117. SPRU, Sussex.
69. J.C. Spender Industry Recipes 1989 Basil Blackwell Oxford
70. R. Sykes The Pharmaceutical Industry in the New Millennium, Capturing the Scientific Promise, Annual Lecture 1997 Centre for Medicines Research (CMR) London
71. D. Teece Profiting from technological innovation: implications for integration, collaboration, licensing and public policy Research Policy 15 1986 285 305
72. R. Whitley Divergent Capitalisms: The Social Structuring and Change of Business Systems 1999 Oxford University Press Oxford
73. Wuyts, S., Colombo, M., Dutta, S., Nooteboom, B. Empirical tests of optimal cognitive distance. Journal of Economic Behaviour and Organization, in press.
74. L.G. Zucker, and M.R. Darby Present at the biotechnological revolution: transformation of technological identity for a large incumbent pharmaceutical firm Research Policy 26 1997 429 446